Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

84.52USD
14 Dec 2017
Change (% chg)

$-0.14 (-0.17%)
Prev Close
$84.66
Open
$84.82
Day's High
$84.93
Day's Low
$84.49
Volume
382,329
Avg. Vol
1,686,922
52-wk High
$86.90
52-wk Low
$69.53

Latest Key Developments (Source: Significant Developments)

Amgen, Novartis announce expanded collaboration with Banner Alzheimer's Institute
Thursday, 2 Nov 2017 04:30pm EDT 

Nov 2 (Reuters) - Amgen Inc :Amgen and Novartis announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program.Amgen - Co, ‍Novartis announced expanded collaboration with Banner Alzheimer's Institute to initiate new trial - API Generation Study 2​.  Full Article

Novartis said to weigh sale of dermatology generics business - Bloomberg
Wednesday, 1 Nov 2017 06:08am EDT 

Nov 1 (Reuters) - :Novartis is said to weigh sale of dermatology generics business which could fetch up to $1.5 billion - Bloomberg citing sources.  Full Article

Novartis submits application to FDA for Kymriah™ (tisagenlecleucel) in adult patients with R/R DLBCL
Tuesday, 31 Oct 2017 02:23am EDT 

Oct 31 (Reuters) - Novartis AG :Novartis submits application to FDA for Kymriah™ (Tisagenlecleucel) in adult patients with R/R DLBCL, seeking second indication for first-ever FDA approved Car-T therapy.Novartis AG - ‍plans to submit additional application for marketing authorization for Kymriah with EMA in DLBCL and pediatric all later this year​.‍plans additional regulatory filings for Kymriah outside US and EU in 2018​.  Full Article

Advanced Accelerator announces $3.9 bln all cash proposed tender offer by Novartis
Monday, 30 Oct 2017 02:00am EDT 

Oct 30 (Reuters) - Advanced Accelerator Applications Sa :Advanced accelerator applications announces $3.9 billion all cash proposed tender offer by Novartis.Novartis will make cash tender offer to acquire all outstanding shares of co, including ADS, for $41 a share and $82 per ADS​.Deal ‍represents 47 percent premium to 30 volume-weighted trading days prior to unaffected share price on nasdaq on Sept 27.Board‍ members, management supportive of transaction; have entered into irrevocable undertakings to tender co's shares into offer​.  Full Article

Biosimilar pegfilgrastim accepted by EMA for regulatory review - Novartis
Friday, 27 Oct 2017 01:27am EDT 

Oct 27 (Reuters) - Novartis Ag :Novartis says Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review.  Full Article

Novartis confirms leadership in multiple sclerosis (ms) with scientific advancements and new data presented
Wednesday, 25 Oct 2017 11:33am EDT 

Oct 25 (Reuters) - Novartis Ag :Novartis confirms leadership in multiple sclerosis (ms) with scientific advancements and new data presented at ECTRIMS.for more information, click: http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20171025:nGNEbTKkG9.  Full Article

GSK will look at Pfizer, Merck consumer assets if offered for sale
Wednesday, 25 Oct 2017 07:47am EDT 

Oct 25 (Reuters) - GlaxoSmithKline CEO Emma Walmsley tells reporters::as world leader in consumer healthcare, we will look at Pfizer consumer health.bulking up consumer is one option but top priority is boosting pharma pipeline.moving forward with Brexit contingency planning, would like to know about transition asap.needs clarity on Brexit implementation phase of at least 2 years.not thinking of any relocation out of UK as a result of brexit.would also look carefully at German Merck consumer assets.new pharma head Miels very focused on launch of 3 critical new products.happy to continue to work with Novartis on consumer health or take over stake if Novartis wants to sell.  Full Article

Novartis CEO: No plans for Sandoz exit, big acquisitions
Tuesday, 24 Oct 2017 09:00am EDT 

Oct 24 (Reuters) - Novartis Ag :CEO Joe Jimenez says focusing on bolt-on acquisitions, larger acquisition "not on strategy".Jimenez says "never say never" to Sandoz divestiture, but "as of today there is really no thought of exiting".  Full Article

Novartis CEO: Alcon spinoff 'probably direction we are headed' - CNBC
Tuesday, 24 Oct 2017 02:20am EDT 

Oct 24 (Reuters) - Novartis Ag :Ceo says wants to time alcon exit when market is strong, expects strong market to continue - cnbc.Ceo says alcon capital markets spinoff probably where we are headed, were we to make a decision - cnbc.Ceo says investing heavily behind entresto, still believes sales to be in range of $500 million in 2017, with blockbuster ($1 billion) sales in 2018 - cnbc.Ceo says does not think u.s. Generics pricing to get better in short term, focusing on sandoz outside the united states- cnbc.  Full Article

Novartis CEO: Novartis shareholders would get Alcon shares in listing
Tuesday, 24 Oct 2017 02:16am EDT 

Oct 24 (Reuters) - Novartis Ag :CEO Joe Jimenez says expects U.S. price pressure on generics business to remain.Ceo says considering separate listing for alcon, shares would go to current novartis shareholders.Ceo says u.s. Tax reform would come into play for deciding alcon listing location.Ceo says not seeing big impact from ocrevus on gilenya sales.Ceo says prescriptions for entresto slowed over july, august before recent pickup.Ceo says hitting Entresto sales target of around $500 million for 2017 will require acceleration.  Full Article

Novartis oncology head Strigini to retire

ZURICH, Dec 15 Novartis oncology head Bruno Strigini will retire next year for personal reasons, the Swiss drugmaker said on Friday, adding that it would announce his successor at a later date.